



Index to Volume 17 (2000)

Subject Index

- A
A antigens, 501
A Glycosyltransferase, 501
ABH antigens, in colon cancer, 331
ABO blood groups, 501
ABO genetic loci, 501
ABO H antigens, expression of, 331
Acetyl coenzyme A, 849
9-*O*-Acetylated sialic acids, 885
N-Acetylgalactosamine 4-sulfatase, 829
N-Acetylgalactosaminide α 2,6-sialyltransferase, 50
N-Acetylglucosamine-6-*O*-sulfotransferase, 43
 cloning of, 587
endo- β -*N*-Acetylglucosaminidases, substrate specificities of, 448
N-Acetylglucosaminyltransferase
 catalytic inverting mechanism of, 40
 crystal structure of, 473
 in *N*- and *O*-glycan branches synthesis, 465
 purification and cDNA cloning of, 47
 structural studies of, 38
N-Acetylglucosaminyltransferase I
 CDNA sequences of, 77
 crystal structure of, 15
N-Acetylglucosaminyltransferase II, from *Arabidopsis thaliana*, 78
N-Acetylglucosaminyltransferase IV, in colorectal cancer, 68
N-Acetylglucosaminyltransferase V
 in hepatocarcinoma, 66
 in hepatocarcinoma, signaling pathway of, 315
 structural studies on, 38
 β -1,6-*N*-Acetylglucosaminyltransferase, 42
 Core2GnT gene for, 70
 Core2GnT gene for, in *C. elegans*, 85
 epidermal growth factor on, 58
 in *O*-glycans biosynthesis, 49
 β -*N*-Acetylglucosaminyltransferase, trimannosyl core and, 451f
N-Acetylhexosaminidase, 829
poly-*N*-Acetylglucosamine
 antigen expression on, 555f
 biosynthesis of, in interferon- γ , 41
 cell surface carbohydrate recognition and, 577
 cloning of, 867
 in interferon- γ production, 893
N-Acetylneuraminic acid (Neu5Ac).
 See also Cytidine 5'-monophosphate *N*-acetylneuraminic acid (CMP-Neu5Ac)
 CMP-sialic acid synthetase and, 51
 with IL-1, 353
 N-glycans on, 55
Achatina fulica, 705, 885
Achatinin-H, 885
Acrosome reaction, 205
Acyl chloride, 787
Addressin (MECA-79), glycosyltransferase and sulfotransferase on, 82
Adenocarcinoma
 ovarian serous, α 1,6 fucosyltransferase expression in, 27
 synthetic vaccines for, 835
Adhesion molecules, 81. See also Cell adhesion
ADHP, 559
Adipic acid hydrazide, CPS derivatives of, 427
AdipoQ, 52
ADP-Glc-pyrophosphorylase, 36
Affinity biosensors, 323
 for rheumatoid arthritis, 323
Affinity enhancement, 543
Agalacto-IgG, 323
Agalactoglycoproteins, galactosylation of, 60
Aggrecan, 607
Air-water interface monolayer, 173
 in CD4-dependent HIV-1 fusion, 199
Airway epithelial cells, 385
 in cystic fibrosis, 385
 Pseudomonas aeruginosa colonization in, 735
 surface membrane glycoforms of, 621
Alcian blue, 761
Alg1-gene, 80
Alg2-gene, 80
Alkaline elimination, 531
Alpha-Gal epitope polymers, 87
Alpha-hemolysin, 613f
Alpha-series ganglioside genes, 64
Alternate complement pathway, 885
Alternate splicing, 42
Alveolar surfactant protein, 543
Alzheimer type dementia, 815
Amadori-modified proteins, 713
Amino acid
 and derivatives, 407
 as teichoic acid fragment model, 273
2-Aminobenzamide, 401
6-Aminoethyl, 543
Amphipathic lipid, 787
Aneurinibacillus thermoaerophilus, 688
Anticoagulant activity, 393
Antifungal vaccine, 677
Antigens
 A, 501
 ABH, in colon cancer, 331
 ABO H, expression of, 331
 poly-*N*-acetylglucosamine and, 555f
 B, 501
 blood group, 553
 blood group, chemistry and immunochemistry of, 531
 carbohydrate, 717
 in colon cancer, H type 1, 331
 differentiation, 553
 Lewis, *c-erbB-2neu* on, 67
 Lewis, capping sequences of, 556f
 oncofetal crypt cell, 307
 tumor-associated, 627
 xenoantigens, α 1,3-galactosyltransferase and, 15
Antisense cDNA, 66
Antithrombin, 597
Apomucin expression, 691
Apoptosis
 with etoposide, 301
 of human hepatocarcinoma cells, 66
Arabidopsis thaliana, 75
 N-acetylglucosaminyltransferase II in, 78
 β 1,2-xylosyltransferase expression in, 77
 fucosyltransferase in, 44
 in gibberellin signaling, 73
 glycosyltransferase cloning in, 44
Archaea, 29
Arionidae, 73
Arthritis, rheumatoid, 323
Arylsulfatase, 63, 829

- Asialo-orosomucoid (ASOR), 875
 Asialoglycoprotein receptor, 543
 Asparagine-linked glycosylation, 767
 Asparagine-linked pentasaccharides, 361
 Aspartate aminotransferase, 70
Aspergillus oryzae, α -mannosidase of, 745
 Assay-anti-cancer compounds, 69
 Assay-capillary electrophoresis, 67
 Assay-glycosyltransferase, 92
 Auto-polysialylation, 20, 50
 Auto-sialylation, 55
 Autoimmune disease, IgG glycosylation pattern in, 81
 Autoradiography, electron microscopic, 261
 AZT, on *N*-linked oligosaccharides, 68
- B**
 B antigens, 501
 B glycosyltransferase, 501
 B lymphocytes, 727
Bacillus polymyxa, 381
 polysaccharide repeating unit of, 684
Bacillus sphaericus, 688
Bacillus stearothermophilus, 684
Bacillus subtilis, SpsA in, 16
 Bacteria
 gram-positive, teichoic acid and, 273
 sialylated lipopolysaccharides in, 33
 Bacterial-NodZ, 17
 Bacterial pathogens, 33
 Basal activity, in hepatocarcinoma cells, 315
 Basigin, 577, 583f
 Big-I antigen, 42
 Bio-gel P-4 column chromatography, 452
 Blood group A
 glycosyltransferases of, 34
 glycosyltransferases of, inhibition of, 67
 Blood group ABO, Lewis antigenic specificity of, 501
 Blood group-active ovarian cyst glycoproteins, 501
 Blood group antigens, 553
 chemistry and immunochemistry of, 531
 Blood group B, glycosyltransferases of, 34
 Blood types, 443
 Brain tissue, 87, 815
 Branch specificity, 875
- C**
 C6 cells glioma cells, 59
C-erbB-2neu, on Lewis antigens, 67
 C-type lectins, 543
 Caco-2 cells, 307
Caenorhabditis elegans, 28
 α 1,2-fucosyltransferase cloning from, 28
 Core2GnT in, 85
 GnT I null mutants of, 71
 GnT II in, 72
 N-glycans in, 472
 renal tubule development in, 33
 Calcium-dependent inverting glycosidases, 29
 Calculations-ab-initio, 40
Caldariella acidophila, 381
 Calnexin
 CFTR and, 810f
 in chaperone-assisted glycoprotein folding, 21
 Calreticulin, in chaperone-assisted glycoprotein folding, 21
Campylobacter jejuni, sialylated lipopolysaccharides in, 33
 Cancer, 26, 27, 68, 69. *See also* specific types, e.g., Adenocarcinoma
 hyaluronidase inhibitors in, 761
 multidrug resistance in, 253
 surface membrane glycoforms in, 617
 vaccine for, 835
Cancer antennarius, 705
 Cancer immunotherapy, MUC1 in, 649
Candida albicans, 677
Candida lambica, 677
Candida tropicalis, 677
 O 139 Capsular polysaccharide, 425
 Carbohydrate antigens, 717
 Carbohydrate-carbohydrate interaction, 62, 627
 Carbohydrate clusters, discontinuous, 844
 Carbohydrate deficient glycoprotein, 24, 25
 Carbohydrate ligands, 553
N-linked carbohydrate processing inhibitors, 41
 Carbohydrate recognition, 567
 Carbohydrate recognition domain, 543
 Carbohydrates, as bacterial attachment sites, 661
 Carboxylic acid group, 705
 Carcinoma. *See also* specific types, e.g., Colon carcinoma
 hyaluronidase inhibitors in, 761
 multidrug resistance in, 253
 surface membrane glycoforms in, 617
 vaccine for, 835
 CARS glycosyltransferases, in glycolipid biosynthesis, 22
 Castanospermine, 859
 Catalytic mechanism, 18, 40
 Caveolae
 in cell adhesion/recognition and signal transduction, 144
 GM1 in, 233
 lipid distribution assessment of, 215
 in multidrug resistance, 253
 in signal transduction via lipid rafts, 153
 Caveolin, in multidrug resistance, 253
 CD4, in HIV-1 fusion, 199
 CD22, 669
 CD77/GB3 synthase gene, cloning of, 64
 CD4-Ick complex, 247
 CDAP, 677
 CDG, 24, 25, 471
 cDNA
 antisense, 66
 encoding acetylglucosamine-6-*O*-sulfotransferase, 43
 on GnT-V, 315
 of GnT-VI, 47
 murine, cloning of, 42
 oligosaccharyltransferase, cloning of, 767
 of plant GnTI sequences, 77
 CDw75, 669
 Cell adhesion
 cell to cell, 59
 glycosphingolipids and, 627
 of infectious diseases, 659
 MUC1 in, 649
 through glycosphingolipid microdomain, 143
 Cell-cell adhesive interactions, HNK-1 epitope in, 59
 Cell culture, autoradiography of, 261
 Cell recognition, through glycosphingolipid microdomain, 143
 Cell surface
 of human colon carcinoma cells, 307
 lipid membrane domains in, 163
 sialic acid in, 301
 Cell surface markers, 582
 Cell surface *O*-glycans, 26
 Cell wall, of *Paenibacillus alvei*, 681
 Cellular myosin heavy chain, 713
Cepaea hortensis, 709
 Ceramide
 glycosylation and, 92, 633
 as signaling molecule, 163
 Ceramide *N*-deacylase, 787
 Cerebellar cell differentiation, ganglioside enriched domains in, 223
 Cerebroside sulfate, galactosylceramide and, 62
 CF (cystic fibrosis). *See* Cystic fibrosis
 CFTR (cystic fibrosis transmembrane conductance regulator), 65, 385, 807
 CFTR transfection, 385
 C2GnT, epidermal growth factor on, 58
 Chagas disease, 71, 727
 Chaperone-assisted glycoprotein folding, 21, 59
 Characterization, 849
 Chemical oversulfonation, 393
 Chinese hamster ovary, 30, 32, 41, 893
 Chloride channel activity, 807
 Chloride secretion, 173
 Cholera toxin, attachment platforms of, 173

- Cholesterol
 in cell surface and vacuolar systems, 163
 in multidrug resistance, 253
 Cholesterol sulfate, 790f
 Chondroitin 4-sulfotransferase, cloning and expression of, 84
 Chondroitin sulfate
 6-*O*-desulfonation, 393
 cell surface carbohydrate recognition and, 577, 586, 588
 cloning of, 84
 in hippocampus, 815
 from lymph nodes, 795
 Chromatofocusing, of MrL, 339
 Cinnamomin, 749
 Clavibacter, 62
 ClcCer synthase inhibitor, 239
 Cleavage secretion, 54
 Cloning
 of α 1,2-fucosyltransferase from *C. Elegans*, 28
 of CD77/GB3 synthase gene, 64
 of CMP-sialic acid synthetase, 51
 of murine cDNA, 42
 of oligosaccharyltransferase, 767
 of P histo-blood group system, 18
 CMP-KDN, 51
 CMP-Neu5Ac. *See* Cytidine 5'-monophosphate *N*-acetylneuraminic acid (CMP-Neu5Ac)
 Cognate polarized trafficking pathways, 181
 Coimmunoprecipitation
 of GM3 and CD4-Ick complex, 223
 of Src protein tyrosine kinases, 223
 Colon cancer
 gp190 in, 307
 H type 1 antigens in, 331
 mucin deglycosylation in, 691
 sialyl- α 2,6-lactosaminyl in, 669
 ST6Gal in, 66
 Colorectal cancer, *N*-acetylglucosaminyltransferase IV in, 68
 Colostrum, 60
 Complement pathway, alternate, 885
 Conformational behavior
 of cancer-associated mucin core, 835
 in ganglioside modeling, 283
 of UDP-glucose, 36
 Congenital disorders of glycosylation (CDG)
 complex *N*-glycans in, 471
 lipid-linked oligosaccharides biosynthesis defects in, 25
 member identification for, 24
 phosphomannose isomerase deficiency in, 25
 Core 2 complex-type *O*-glycans, 49
 Core2GnT gene, 70
 Corpora amylacea, 815
 COS-1 cell expression, 767
 Crustacean lectin, 339
 Crypt cell antigen, oncofetal, 307
Cryptococcus laurentii, 677
 Csk kinase, 223
 Cyanopyridinium agent (CDAP), 677
 Cysteine residues
 in α 1,3/4-fucosyltransferase, 48
 in fucosyltransferases VII, 20
 Cystic fibrosis, 385
 fucosyltransferases in, 65
 N-linked oligosaccharide addition in, 807
 Pseudomonas aeruginosa binding in, 735
 salivary mucins sulphation in, 65
 terminal glycosylation in, 617
 Cystic fibrosis transmembrane conductance regulator, 385, 620
 Cytidine 5'-monophosphate *N*-acetylneuraminic acid (CMP-Neu5Ac), conformational investigation of, 57
 Cytokine, glycosylated IL-1, 353
 Cytoplasmic, transmembrane, and stem (CTS) region, golgi glycosyltransferase, 58
 D
 3D-QSAR, 38
 Deacylation, 787
 Deanimoneuraminic acid (KDN), 51
 biosynthesis of, 51
 Degenerative changes, 815
 Deglycosylation, of mucins, 691
N-linked Deglycosylation, on ST3Gal III, 52
 Delayed graft function, 57
 Dentate gyrus, 815
 Dermatan sulfate
 6-*O*-desulfonation of, 393
 chemoenzymatic preparation of, 829
 cloning of, 84
 6-*O*-Desulfonation, 393
 Detergent-insoluble material, 143
 Detergent-insoluble membrane, of sea urchin sperm, 205
 Detergent-insoluble microdomain, of Lewis cells, 239
 Development
 of *Caenorhabditis elegans*, 33, 71, 85
 in mouse, 45, 84
 of *N*- and *O*-glycan branches, 465
 neural, 50
 DHPE, 559
 Diarrhea, 173
 Differentiation
 of cerebellar granule cells, 223
 of oligodendrocytes, 181
 Differentiation antigens, 553
 Disulfide bond, 20, 37
 DNA. *See* cDNA
 Docking enzyme substrate, 38, 39
 Dolichols
 cell surface carbohydrate recognition and, 577
 chain length of, 76
 Double lysine motif, 776
 Down's syndrome, 815
Drosophila melanogaster, 42
 glycosyltransferase cloning in, 44
 glycosyltransferase of, 867
 GnT I cloning from, 72
 N-glycans in, 473
 Drug resistance. *See* Multiple drug resistance
 Dystroglycan, 443
 in peripheral nerve, 458
 α -Dystroglycan, glycosylation of, 407
 E
E. coli, surface adhesion of, 660
 Eel serum, 505t
 Electron microscopic autoradiography, 261
 Electrospray ionization mass spectrometry, 829
 Elk-1 transcription factors, 69
 Embigin, 577
 Embroglycan, 581
 Embryonic development, 553
 Endo- β -*N*-acetylglucosaminidases, substrate specificities of, 448
 Endo- β -*N*-galactosidase, 577
 Endocytosis, 163
 Endoglycosidases
 cell surface carbohydrate recognition and, 577
 glycoproteins and, 578
 ribosome-inactivating proteins and, 749
 Endomannosidase, immunolocalization, 61
 Endoplasmic reticulum
 α -mannosidase of, 745
 glycoprotein folding in, 21
 glycoprotein folding in, quality control of, 59
 N-glycan trimming in, 18
 Enterocyte differentiation, 307
 Enterocytic functions, 173
 Envelope glycoprotein, in HIV-1, 401
 Epidermal growth factor, 58
 inhibition of, 718
 Epithelial airway cells
 in cystic fibrosis, 385
 Pseudomonas aeruginosa colonization in, 735
 surface membrane glycoforms of, 621
 Epithelial intestinal cells, 173
 Epitopes, in blood group antigens, 531
 Equine submandibular gland, 849
 Erythrocytes, 885
 Ester, of amino acids, 273
 ET18-OCH₃, on GnT-V, 315
 Ethylenediaminetetraacetic acid, 681
 Etoposide, apoptosis from, 301
 Eukaryotes, *N*-linked protein glycosylation in, 29
 Evolution, of *N*- and *O*-glycan

- branches, 465
 EXT1 gene, 31
 in heparan sulfate biosynthesis, 83
 EXT2 gene, 31
 in heparan sulfate biosynthesis, 83
 External envelope glycoprotein, in HIV-1, 401
 Extravasation, galectin-3 in, 81
- F
 FAC-MS, 88
 Farnesylpyrophosphate, 76
 Fertilization, 205
 Fibronectin, 569
 Fimbriae, 659
Flavobacterium, 579
 Flowcytometry, in Jurkat cell apoptosis, 301
 5-Fluorouracil, NeuAc-IL-1 and, 353
 Fringe proteins, 32
 identification of, 867
 notch glycoproteins and, 86
 Frontal affinity chromatography/mass spectrometry, for GlcNAc-T-V inhibitor libraries, 34
 FTIR, 63
 Fuc-TIX, 49
 α 1,3-Fucose
 in cystic fibrosis cell glycosylation, 385
 in cystic fibrosis terminal glycosylation, 617
 Fucose, in hippocampus, 815
 α 1,6-Fucose, in cystic fibrosis cell glycosylation, 617
 Fucosyltransferase(s)
 in cystic fibrosis airway, 65
 Lewis family and, 519
 N-terminal glycosylation of, 859
 structure-function studies of, 17
 in xyloglucan biosynthesis, 78
 α 1,2-Fucosyltransferase
 cloning of, from *C. Elegans*, 28
 in H type 1 antigen expression, 331
 α 1,3-Fucosyltransferase
 from *Arabidopsis*, 44
 gene *c-erbB-2neu* on, 67
 α 1,3/4-Fucosyltransferase
 cysteine residues of, 48
 pyridoxal-5'-phosphate/ NaBH_4 in, 48
 α 1,6 Fucosyltransferase, in ovarian serous adenocarcinoma, 27
 α 1,3/4-Fucosyltransferase III, C-terminal *N*-glycosylation sites of, 43
 α 1,3-Fucosyltransferase IV, regulatory mechanisms of, 69
 α 1,3-Fucosyltransferase VI, in Weibel-Palade bodies, 22
 Fucosyltransferase VII, cysteine residues in, 20
 Fungi, α -mannosidase of, 745
 Fusion, CD4-dependent HIV-1, 199
 Fut9
 in knock-out mouse, 86
 in Lewis x structure, 87
- G
 G258 mutant, 79
 α Gal-epitope, 35, 39, 87, 88, 89
 α Gal-polymer, 87
 β 4Gal-T1, prolactin and, 80
 Galactocerebrosides, in myelin sheath biogenesis, 184
 Galactoglucosylomannan conjugate, 677
 Galactose, in hippocampus, 815
 Galactose-specific lectin, 749
 β -Galactoside sulfotransferase, GP3ST, 47
 Galactosphingolipids, in myelin sheath biogenesis, 181
 Galactosylation, of agalactoglycoproteins, 60
 Galactosylceramide, cerebroside sulfate and, 62
 α 1,3-Galactosyltransferase
 bovine structure of, 37, 39
 crystal structure of, 15
 fusion with UDP-galactose 4-epimerase, 35
 Galactosyltransferase, in xyloglucan biosynthesis, 78
 β 1,4-Galactosyltransferase, in mouse intestine, 84
 Galectin-3, 570
 in neutrophil extravasation, 81
 Galectins, 549, 553
 Ganglioside. *See also* specific types, e.g., GM1 ganglioside
 α -series, 64
 and CD4-Ick complex, 247
 conformational analysis of, 283
 expression of, in tumor cells, 717
 of sea urchin sperm, 205
 in signal transduction via lipid rafts, 153
 and Src family tyrosine kinase, 223
 Ganglioside enriched domains, in cerebellar cell differentiation, 223
 Ganglioside-modulated integrin receptor function, 635
 ppGaNTase-T1, expression of, in *Pichia pastoris*, 45
 ppGaNTase-T2
 characterization of, 44
 expression of, in *Pichia pastoris*, 45
 spatial expression patterns of, 45
 ppGaNTase-T3, expression of, in *pastoris*, 45
 ppGaNTase-T9, 46
 Gastropods
 N-glycans of, 73
 marine, 577
 GD0039, 70
 Gel electrophoresis, polyarylamide, 833f
 Gel filtration chromatography, 750
 Gel zymography, 761
- Genetic polymorphism, 649
 Gibberellin signaling, 73, 74
 β 1,4-Galactosyltransferase
 from *Arabidopsis*, 44
 in *N*-linked sugar chain biosynthesis, 46
 phosphorylation of, 60
 β 4-Galactosyltransferase-I, in murine spermatogenesis, 19
O-GlcNAc-transferase, functions of, 27
 GlcNAc-T-V, inhibitor libraries evaluation of, 34
 Glioma, 717
 C6 cells, 59
 Globotriaosylceramide, CD77/GB3 synthase gene for, 64
 α -Glucan, 36
N-acetyl Glucosamine, in hippocampus, 815
 Glucose, on *Thermus thermophilus* β -glycosidase, 377
 Glucose absorption, 173
 Glucose trimming, by ER glucosidase II, 61
 Glucosylceramide
 in multidrug resistance, 253
 multidrug resistance and, 166
 Glucosyltransferase(s)
 α -3, deficiency of, 24
 modeling of, 39
 in *Thermus caldophilus*, 36
 Glucosyltransferase Core2L, modeling of, 40
 Glucuronyltransferases, for HNK-1 epitope, 35, 875
 Glycan mapping, 401
N-Glycans
 acceptor specificity of, for GlcAT-P, 875
 N-acetylglucosaminyltransferase on, 465
 of gastropods, 73
 of human interferon- γ , 41
 linked pentasaccharide synthesis of, 361
 processing and quality control of, α 1,2, mannosidase in, 18
 and ST8SIA II, 55
 and ST8SIA IV, 55
O-Glycans
 N-acetylglucosaminyltransferase on, 465
 biosynthesis of, β -1,6-*N*-acetylglucosaminyltransferase in, 49
 of cell surface, 26
 core 2 complex-type, 49
 Ser/Thr linked, 474
 Glycans, function of, 567
 Glycation
 of fructosyllysine, 713
 of teichoic acid, 273
 Glycoconjugates, in dentate gyrus, 815
 Glycoinositolphospholipids, from *Trypanosoma cruzi*, 727
 Glycolipids

- bacteria adhesion and, 659
- biosynthesis of, CARS and HY-CARS glycosyltransferases in, 22
- in blood group antigens, 531
- in CD4-dependent HIV-1 fusion, 199
- host pathogens and, 173
- phase behavior of, 63
- Glycolipids enriched microdomain (GEM), 233
- Glycomimetics, 640
- Glycopathology, 443
- Glycopeptide
 - of cancer associated mucin core, 835
 - of cinnamomin, 749
 - with mannosyl serine/threonine linkage, 407
 - in mucin-type, sialylation of, 55
- Glycoprotein(s)
 - N*-acetylglucosaminyltransferase on, 465
 - poly-*N*-acetylglucosamine and, 867
 - bacteria adhesion and, 659
 - blood group-active ovarian cyst, 501
 - folding of, in endoplasmic reticulum, 59
 - fucosyltransferase and, 859
 - with mannosyl serine/threonine linkage, 407
- Glycosaminoglycans (GAGs)
 - dermatan sulfate as, 829
 - hyaluronidase inhibitors and, 761
 - from lymph node, 795
 - O*-sulfonated, 393
- Glycosidases, calcium-dependent inverting, 29
- β -Glycosidases, of *Thermus thermophilus*, 377
- Glycoside cluster effect, 543
- Glycoside hydrolase family 1, 377
- Glycosidic linkage, unnatural, 361
- Glycosphingolipid microdomain
 - cell adhesion and signal transduction through, 143
 - in signal transduction via lipid rafts, 153
- Glycosphingolipid signaling domain, 143
- Glycosphingolipids
 - deficiency of, on microdomain formation, 239
 - general functions of, 144f
 - in myelin sheath biogenesis, 181
 - in signal transduction via lipid rafts, 153
- Glycosylation
 - N*-acetylglucosaminyltransferase in, 465
 - asparagine-linked, 767
 - CFTR and, 807
 - congenital disorders of (See Congenital disorders of glycosylation)
 - of cystic fibrosis cells, 385
 - of α -dystroglycan, 407
 - Golgi apparatus in, 465
 - insect cell pathway of, 75
 - in rheumatoid arthritis, 323
 - Trk protein and, 233
- N*-Glycosylation
 - of fucosyltransferase, 859
 - of gp160, 401
 - of hepatitis C, 30
 - malignant alteration of, 454
 - organ and species specific, 454
 - site-directed, 453
- N*-linked protein Glycosylation, in eukaryote origin, 29
- O*-Glycosylation
 - of adjacent serine residues, 835
 - of gp190, 307
 - MUC1 and, 649
 - in mucin-type glycopeptides, 55
 - in renal canal development, 33
- Glycosylphosphatidylinositol (GPI), in signal transduction via lipid rafts, 153
- Glycosyltransferase(s)
 - on addressin (MECA-79), 82
 - assay, 92
 - in blood group A and B, 34
 - in blood group ABO, 501
 - of blood group genes, 512
 - catalytic domains of, common features in, 17
 - cloning of, from genetic model organisms, 44
 - in *Drosophila melanogaster*, 867
 - EXT1 and EXT2, 31
 - Fringe, 86
 - in golgi body, mediation of, 58
 - in sialyl- α 2,6-lactosaminyl biosynthesis, 669
 - SpsA, 16
 - UDP-GlcNAc biosynthesis and, 17
- GM1 ganglioside
 - headgroups of, 283
 - photoactivable, 215
 - Trk protein and, 233
- GM2 ganglioside, headgroups of, 283
- GM3 ganglioside, 247
 - and CD4-Ick complex, 247
 - in cell adhesion/recognition, 143
 - deficiency of, on microdomain formation, 239
 - genomic structures and expression characteristics of, 56
- GM2 synthase, disulfide bond locations in, 37
- GnT (*N*-Acetylglucosaminyltransferase). See Acetylglucosaminyltransferase
- GnT-V
 - in hepatocarcinoma, 66
 - in hepatocarcinoma, signaling pathway of, 315
- Goblet cells, 331
- Golgi β 1-6*N*-acetylglucosaminyltransferase V (Mgat5), 26
- Golgi body
 - α 1,3-galactosyltransferase in, 15
 - α -mannosidase of, 745
 - β 3GnT localization in, 867
 - cystic fibrosis transmembrane conductance regulator in, 390
 - in glycosylation, 465
 - glycosyltransferase mediation in, 58
 - GM2 synthase in, 37
 - immunolocalization of endomannosidase in, 61
 - protein mannosylation in, 76
- Golgi localization, 867
- Gonadotropin, human chorionic, *N*-linked sugar chains in, 453f
- GP160, 401
- GP190, 307
- Gram-positive bacteria, teichoic acid and, 273
- Growth factors, heparin and, 597
- H
- H antigens, 501
 - in colon cancer, 331
- H glycosyltransferase, 501
- Haemagglutination inhibitor, 705
- Haemophilus influenzae*
 - fucose binding proteins of, 385
 - sialylated lipopolysaccharides in, 33
- Helicobacter pylori*, adhesion of, 660
- Hematoxylin, 815
- Hemicentrurus pulcherrimus*, 205
- Hemolysis, 885
- Hemophilus influenzae*, anti-adhesive agents for, 659
- Heparan sulfate. See also Heparin
 - biosynthesis of, EXT1 and 2 in, 31, 83
 - biosynthesis of, infrastructure of, 32
 - cell surface carbohydrate recognition and, 577
 - 6-*O*-desulfonation of, 393
 - overview of, 597
- Heparin
 - 6-*O*-desulfonation of, 393
 - from lymph node, 795
 - overview of, 597
- Hepatic receptors, 556
- Hepatitis C, delayed *N*-glycosylation of, 30
- Hepatocarcinoma
 - Gnt-V on, 66
 - signal transduction in, 315
- Heteroglycans, 567
- Hexosamine, 393
- Hexuronate, 393
- Hippocampal formation, 815
- Histone chromosomal proteins, 84
- HIV-1, 173
 - attachment platforms of, 173
 - CD4-dependent fusion of, 199
- HIV-1 envelope glycoprotein, 401
- HNK-1 epitope
 - in cell-cell adhesive interactions, 59

- glucuronyltransferase for, 875
 structure and function of, 35
Homo sapiens, α 1,2, mannosidase in, 18
 Homology protein model, of UDP-GlcNAc, 38
 Host pathogens, 173
 Human α 1,2, mannosidase, 18
 Human chorionic gonadotropin, *N*-linked sugar chains in, 453, 453f
 Human colon carcinoma, gp190 in, 307
 Human GnT I, 41
 Human hepatocarcinoma
 7721 cells, 67
 Gnt-V on, 66
 signal transduction in, 315
 Human interferon- γ , poly-*N*-acetylglucosamine biosynthesis in, 41
 Human milk, oligosaccharides in, 443
 HY-CARS glycosyltransferases, in glycolipid biosynthesis, 22
 Hyaluronan
 6-*O*-desulfonation of, 393
 hyaluronidase inhibitor detection and, 761
 from lymph node, 795
 retrospective of, 607
 Hyaluronan synthase
 enzymological characterization of, 83
 of *Pasteurella multocida*, 82
 Hyaluronic acid, 761
 Hyaluronidase inhibitors, 761
 Hydrazinolysis, 453
- I
 Iduronate, 393
 Iduronic acid, heparin and, 597
 Iduronidase, substrates for, 829
 IgG, in rheumatoid arthritis, 323
 IgG glycosylation, in autoimmune disease, 81
 IGnT B, 42
 Immune function
 sialyl- α 2,6-lactosaminyl in, 673
 sialyltransferase mediators in, 31
 Immunoglobulin, 727
 Immunoglobulin superfamily, 577
 Immunohistochemistry, 691
 Immunolocalization
 of endomannosidase, in golgi body, 61
 of OST48, 776f
 Immunotherapy, 835
 Infectious disease, 659
 Inflammation, 553
 Insect cell, glycosylation pathway of, 75
 Integrin, Mgat5 *N*-glycans regulation of, 26
 Interferon- γ
 poly-*N*-acetylglucosamine biosynthesis in, 41
 sialylation of, 893
 Interleukin-1, with Neu5Ac, 353
 Intestinal absorption and secretion, 173
- Ion channel, 807
 cis-Isoprenyltransferase, 76
- J
 Jurkat cells, sialic acid in, 301
- K
 Kidney transplant patients, ST6Gal in, 57
 Kifunensine, 748f
 Kinetics, of *Thermus thermophilus* β -glycosidase, 377
- L
 L-PHA, 70
 L-Selectin ligands, core structures of, 30
 Labeling, tritium, 261
 Lactosamine, sialic acid addition to, 669
 Lactosylated polylysine gene therapy vector, 617
 Le-gene specified glycosyltransferase, 501
 Le^a antigens, 501
 Le^b antigens, 501
 LEC12, 49
 LEC29, 49
 Lectin-histochemical staining, 815
 Lectins
 bacteria adhesion and, 659
 C-type, 543
 cell surface carbohydrate recognition and, 577
 function of, 567
 galactose-specific, 749
 of *Macrobrachium rosenbergii*, 339
 of *Psathyrella velutina*, 323
 specificity of, 705
Leishmania, phosphoglycans of, 28
Leishmania major, STT3 homolog of, 74
 Leukocyte adhesion, 553
 Leukosialin, 49
 Lewis antigens
 capping sequences of, 556f
 gene *c-erbB-2neu* on, 67
 Lewis blood groups, 501
 Lewis cells, glycosphingolipid deficiency on, 239
 Lewis genetic loci, 501
 Lewis x structure
 cell surface carbohydrate recognition and, 577
 Fut9 and, 87
Limax flavus, 709
Limulus polyphemus, 709
 Link protein, 607
 Lipid, amphipathic, 787
 Lipid-linked oligosaccharides, in congenital disorders of glycosylation, 25
 Lipid rafts
 in multidrug resistance, 253
 in signal transduction, 153
 Liposomes, carbohydrate-carbohydrate interactions in, 62
- Lotus tetragonolobus*, 505t
 Lymph nodes, chondroitin sulfate from, 795
 Lymphocytes
 B, 727
 GM3 and CD4-Ick complex in, 247
 homing of, 30
 raft-based signaling in, 191
 Lysobisphosphatidic acid, 163
 structure of, 168f
 Lysosomal exoglycosidase deficiencies, 457
 Lysosomal storage disease, 23
- M
Maackia amurensis, 301
Macrobrachium rosenbergii, 339
 Macrophage endocytosis receptor, 557
 Magnetic resonance imaging (MRI), in ganglioside conformational analysis, 283
 Malignancy. *See* Tumor malignancy
 Mannan conjugate, 677
 Mannose, in hippocampus, 815
 Mannose 6-phosphate pathway, 23
 Mannose-PO₄-transferase, of *Leishmania*, 28
 Mannose sugar chains, structural rules for, 449
 α -Mannosidase, 745
 α 1,2, Mannosidase(s)
 class I, 29
 in *N*-glycan processing and quality control, 18
 Mannosidase II inhibitors, development of, 38
 Mannosyl serine/threonine linkage, 407
 Mannosyltransferase genes, 80
 Mapping, glycan, 401
 Marine gastropods, 577
 Mass spectrometry, 553
 MECA-79, glycosyltransferase and sulfotransferase on, 82
 Membrane, in CD4-dependent HIV-1, 199
 Membrane domain, in myelin sheath biogenesis, 181
 Memory, 815
 Metastasis, *N*-acetylglucosaminyltransferase IV in, 68
 Metastasis-related phenotype, 66
 Mgat5 *N*-glycans, 26
 Micelle, 787
 Microdomains
 in CD4-dependent HIV-1 fusion, 199
 GM3 and CD4-Ick complex in, 247
 as host pathogen attachment platforms, 173
 in signal transduction in Lewis cells, 239
 in signal transduction via lipid rafts, 153
 Microsomal enzyme, of *Aspergillus oryzae*, 745

- Microsomes, 849
 Midkine, 577, 585
 Milk oligosaccharide, 443
 Molecular dynamics, in ganglioside modeling, 283
 Molecular mechanics, in ganglioside modeling, 283
 Monoclonal antibodies
 for colon carcinoma cell recognition, 307
 on glioma cells, 717
 research progress in, 553
 Monosaccharide, as teichoic acid fragment model, 273
 Mouse, β 1,4-galactosyltransferase in, 84
 MRI (magnetic resonance imaging), in ganglioside conformational analysis, 283
 Mrl isoforms, 339
 MUC1 mucin, 649, 691
 glycosylations vs. conformation preferences in, 835
 MUC2 mucin, 691
 MUC3 mucin, 691
 Mucin carbohydrates, epidermal growth factor on, 58
 Mucins
 in blood group antigens, 531
 deglycosylation of, 691
 Pseudomonas aeruginosa binding to, 735
 salivary, in cystic fibrosis, 65
 Mucosa cells, H type 1 expression in, 333
 Multi-valent interaction, 543
 Multiple drug resistance
 in glycolipid biosynthesis, 23
 lipid rafts and caveolar membranes in, 253
 Multivesicular endosome, 163
 Muramic acid, 681
 β -1,6-*N*-Murine acetylglucosaminyltransferase, 42
 Murine β 4-galactosyltransferase-I, in spermatocytes, 19
 Murine cDNA, cloning of, 42
 Murine spermatogenesis, 19
 Mutagenesis, site-directed, 859
 Mutation, 807
 Myc-peptide sequence, 767
 Myelin, 181
 Myeloglycan, 635
 Myelosuppression, IL-1 on, 353
 Myosin heavy chain, 713

 N
 Natural killer (NK) cells, raft-based signaling in, 191
Neisseria gonorrhoeae, sialylated lipopolysaccharides in, 33
Neisseria meningitidis
 CMP-Neu5Ac in, 57
 sialylated lipopolysaccharides in, 33

 Neoglycoconjugates, 735
 Neoglycolipid technology, 558
 Neoglycoprotein
 in IL-1, 353
 research progress in, 553
 Nerve, peripheral, dystroglycan in, 458
 Nerve growth factor receptor, 233
 Neu5Ac (*N*-acetylneuraminic acid). *See* Acetylneuraminic acid (Neu5Ac)
 Neural cell adhesion molecule (NCAM)
 retinoic acid and, 781
 ST8SIA IV on, 50
 Neuraminidase, 577
 Neuritogenesis, ganglioside-induced, 147
 Neuroblastoma cells, sialyltransferase induction in, 781
 Neuronal axons, myelin sheath of, 181
 Neuronal cell cultures, 223
 Neurotrophins, 233
 Neutrophil, extravasation of, galectin-3, 81
Nicotiana tabacum, GnTI coding of, 77
 NK cells, raft-based signaling in, 191
 NMR (nuclear magnetic resonance spectroscopy), 681
 of cancer-associated mucin, 835
 in glycopeptide structural studies, 749
 NodZ, 17
 NOE connectivities, 840
 Non-receptor tyrosine kinases, 223
 Normal phase chromatography, 401
 Notch glycoproteins
 Fringe proteins and, 86
 signaling modulation in, 32
 NOx, IL-1 on, 353
 Nuclear magnetic resonance (NMR) spectroscopy, 681
 in cancer-associated mucin core, 835
 in glycopeptide structural studies, 749
 Nucleolin, 713
 Nucleotide-diphospho-sugar transferase, of *Bacillus subtilis*, 16

 O
 O 139 capsular polysaccharide, 425
 Oligodendrocytes, 181
 carbohydrate-carbohydrate interactions in, 62
 Oligomannose *N*-glycans, 468f
 Oligosaccharide(s)
 bacteria adhesion and, 659
 in blood group antigens, 531
 of dermatan sulfate, 829
 α -dystroglycan, 407
 of human blood group glycoproteins, 508t
 of milk, 443
 of ovarian cysts glycoproteins, 509t, 510t
 sialylation in, 669
 synthesis of, blood group antigens and, 531
 synthetic vaccines from, 829
 Oligosaccharide ligands, research progress in, 553
 Oligosaccharide probes, 553
N-linked Oligosaccharides
 AZT on, 68
 CFTR mutation on, 807
O-linked Oligosaccharides, glycosyltransferase Core 2L and, 40
 Oligosaccharyltransferase
 CFTR mutation on, 807
 from pig, 767
 OligoSia-containing glycoprotein, 52
 Oncofetal crypt cell antigen, 307
 Ontogenesis, polysialyltransferases in, 21
 Ontogenic development, 627
 Ontogenic transformation, 627
Oryctolagus cuniculus, *N*-acetylglucosaminyltransferase I of, 15
 OST48, 767
 Ovarian cysts, 503
 Ovarian serous adenocarcinoma, α 1,6 fucosyltransferase expression in, 27
 Ovine placenta, 705

 P
 P histo-blood group system, 18
p Phenotype, molecular basis of, 18
Paenibacillus alvei, 681
 Pancreatic trypsin, 787
Pasteurella multocida, hyaluronan synthase of, 82
 Pathogens, glycolipids and, 173
 PC 12 cells, 233
 PCrk cells, 233
 Pentasaccharides
 anti-adhesive activity of, 659
 trimannosyl core of, 449
N-Pentasaccharides, with isomeric glycosidic linkage, 361
 Peptidoglycan, 681
 Periodate oxidation, 691
 Peripheral blood lymphocytes, GM3 and CD4-Ick complex in, 247
 Peripheral nerve, dystroglycan in, 458
 Phase behavior, of glycolipids, 63
Phaseolus vulgaris, 467
 Phosphoglycans, of *Leishmania*, 28
 Phosphoinositide 3-kinase, 315
 Phosphomannose isomerase deficiency, 24
 Phosphorylation, of 1,4-galactosyltransferase, 60
Pichia pastoris, EXT1 and EXT2 in, 31
 Plant cell wall, biosynthesis in, 78
 Plant hormone signaling, 73
 Plasma membrane
 lipid distribution assessment of, 215
 Src family kinases in, 223
 Platelet derived growth factor, inhibition of, 718
 P_o, 443

- Polarized trafficking pathways, 181
 Polyarylamide gel electrophoresis, 833f
 Polylactosamine glycans, 307
 Polylysine gene therapy vector, lactosylated, 617
 Polymers, alpha-Gal epitope, 87
 Polypeptide *N*-acetylgalactosaminyl-transferase
 characterization of, 44
 expression of, in *Pichia pastoris*, 45
 spatial expression patterns of, 45
 T9, 46
 Polyprenol-P: *N*-acetylhexosamine-1-P transferase family, 61
 Polysialic acid
 in neural cell adhesion molecule, 50
 in rainbow trout egg PSGP, 50
 retinoic acid and, 781
 synthesis of, 21
 terminal glycosylation and, 617
 Potato, GnTI coding of, 77
 ppGaNase-T1, expression of, in *Pichia pastoris*, 45
 ppGaNase-T2
 characterization of, 44
 expression of, in *Pichia pastoris*, 45
 spatial expression patterns of, 45
 ppGaNase-T3, expression of, in *pastoris*, 45
 ppGaNase-T9, 46
 Primary structure, 749
 Prolactin, on B-cells, 80
 Proliferation, 717
N-linked Protein glycosylation, in eukaryote origin, 29
 Protein kinase B, 315
 Protein tyrosine kinase, 191
 Proteoglycan
 hyaluronan as, 607
 hyaluronidase inhibitors and, 761
 from lymph node, 795
Psathyrella velutina lectin, 323
Pseudomonas aeruginosa, 385, 688
 sialyl-Le^x receptors for, 735
 Psychological stress, on sialyltransferase activity, 54
 Pyranose ring, 849
 Pyridoxal-5'-phosphate/NaBH₄, *iv*
 α 1,3/4-Fucosyltransferase, 48
 Pyridylaminated-oligosaccharides, 876
 Pyrophosphate bridge, 681
- R
 Rabbit, *N*-acetylglucosaminyltransferase I of, 15
 Rafts, 163
 in microdomain formation, in Lewis cells, 239
 in multidrug resistance, 253
 in myelin sheath biogenesis, 181
 in transmembrane signaling, 191
 Ras/Raf-1/MEK/MAPK cascade, 315
- Receptors
 asialoglycoprotein, 543
 fructosyllysine, 713
 hepatic, 556
 macrophage endocytosis, 557
 nerve growth factor, 233
 for *Pseudomonas aeruginosa* sialyl-Le^x, 735
 Red cells, ABH and Lewis antigens on, 511
 cis-Regulatory element, 80
 Renal tubule development, in *C. elegans*, 33
 Retinoic acid, sialyltransferases induction with, 781
 Retinoic acid-induced differentiation, 53
 RGP-160, 401
 Rheumatoid arthritis, 323
 Rhodopsin, 443, 456f
 Ribophorin I, 767
 Ribophorin II, 767
 Ribosome-inactivating protein, 749
 Ricin resistant cells, 569
Ricinus communis, 301
 RNase B, enzymatic modification of, 79
 ROESY connectivities, 840
- S
 Saccharide hydroxyl groups, CDAP activation of, 677
Saccharomyces cerevisiae
 α 1,2, mannosidase in, 18
 protein mannosylation in, 76
 Salivary mucins, in cystic fibrosis, 65
Salmonella enterica, 688
Sambucus nigra, ST6Gal in, 66
 Saponification, 849
 Schizophrenia, 815
Scilla serrata, 709
 Sea urchin, 205
 Secondary cell wall polymer, 681
 Secretor, 331
 Selective branch scission method, 878
 Selectins, 553
 Selective 6-*O*-desulfonation, 393
 Seminolipid, 787
 Septic shock, teichoic acid and, 273
 Sequential exoglycoside digestion, 452
 Serial lectin affinity chromatography, 452
 Serine/threonine linkage, 407
 Serine trimer, 835
 Serum amyloid A, 353
 Serum glucose, IL-1 on, 353
 7721 cells, 315
 Sialate-4-*O*-acetyltransferase, 849
 Sialic acid(s)
 binding site specificity of, 705
 biosynthesis of, 487
 catabolism of, 489
 in cystic fibrosis cell glycosylation, 385, 617
 diversity of, 485
 enzymatic 4-*O*-acetylation of, 849
 enzymatic modification of, 20
 future aspects of, 495
 in hippocampus, 815
 and IL-1, 353
 occurrence, isolation and analysis of, 485
 physiological and pathophysiological roles of, 493
 research achievements of, 485
 Sialic acid specific lectin, 339
 9-*O*-acetylated Sialic acids, 885
 poly α 2,8 Sialic acids, 617
 Sialidase, in cell surface, 301
 Sialoadhesion family, 353
 Sialoglycoproteins, 781
 Sialyl-Lewis x, 735
 Sialylation
 of glycopeptide, mucin-type, 55
 of interferon- γ , 893
 α 2,6-Sialylation, 669
 α 2,3-Sialylation, in gp190, 307
 Sialyltransferases
 alpha-series ganglioside genes for, 64
 bacterial lipopolysaccharide, 33
 as immune function mediators, 31
 interferon- γ and, 893
 in Jurkat cells, 301
 psychological stress on, 54
 retinoic acid induction of, 781
 in sialyl- α 2,6-lactosaminyl biosynthesis, 669
 ST8SIA IV, 53
 Signal transducer molecules, 143
 Signal transduction. *See also* Signaling
 glycosphingolipids in, 627
 GM3 enriched domains in, 247
 in hepatocarcinoma cells, 315
 in host pathogen attachment platforms, 173
 MUC1 in, 653
 of sea urchin sperm, 205
 Src family kinases in, 223
 through glycosphingolipid microdomain, 143
 Trk protein in, 233
 via lipid rafts, 153
 Signaling
 gibberellin, 73, 74
 notch glycoproteins in, 32
 transmembrane, 191
 Signaling platform, 191
 Site-directed mutagenesis, 17, 29, 33, 48, 55, 83, 859
 Sodium dodecyl sulfate, 681
Solanum tuberosum, GnTI coding of, 77
 Sperm, 205
 Spermatocytes
 arylsulfatase-A in, 63
 murine β 4-galactosyltransferase-I in, 19
 Sphingolipid(s)
 in cell surface and vacuolar

- systems, 163
 - mammalian pathways of, 164f
 - on pancreatic trypsin, 787
 - and Src family tyrosine kinase, 223
 - in transmembrane signaling, 191
- Sphingolipid domains, autoradiography for, 261
- Sphingolipidosis, 163
- Sphingomyelin, 143
 - in caveolae bilayer, 215
- Sphingomyelinase, 166f
- SPINDLY (SPY) protein, in gebberellin signaling, 73, 74
- Spore coat, of *Bacillus subtilis*, 16
- SpsA, of *Bacillus subtilis*, 16
- Src family kinases
 - in cell adhesion/recognition, 143
 - in cerebellular cell differentiation, 143
 - in microdomain formation, 239
 - in peripheral blood lymphocytes, 247
 - PTKs, 193
 - in signal transduction via lipid rafts, 153
- Src family tyrosine kinase
 - with ganglioside, 223
 - in peripheral blood lymphocytes, 223
- Staining, lectin-histochemical, 815
- ST6Gal
 - cleavage-secretion differences in, 54
 - cloning, expression, and characterization of, 53
 - hepatic transcript expression of, 66
 - in kidney transplant patients, 57
 - transcription control of, 19
- ST3Gal III, *N*-linked deglycosylation on, 52
- ST6Gal.I, 669
- Stn, synthetic vaccines from, 829
- Streptococcus pneumoniae*, anti-adhesive agents for, 659
- Streptomyces*
 - endoglycosidase of, 579
 - tunicamycin biosynthesis in, 62
- Stress, on sialyltransferase activity, 54
- Strongylocentrotus purpuratus*, 205
- Structural properties, 767
- Structure determination, 681
- STT3 homolog, of *Leishmania major*, 74
- Subcellular localization, 767
- Submandibular gland, equine, 849
- Substrates, for iduronidase, 829
- N*-linked Sugar chains, 73
 - biosynthesis of, 450f
 - biosynthesis of, β 1,4-Galactosyltransferase, 46
 - in hCG, 453, 453f
- Sugar malabsorption, 176
- Sugars, anti-adhesive properties of, 662
- Sulfated glycans, 584
- Sulfo-sialyl-Lewis x, 735
- Sulfolobus solfataricus*, 381
- Sulfotransferase
 - cell surface carbohydrate recognition and, 577
 - GP3ST, 47
 - heparin and, 597
- Sulphatide, 787
- Surface layer, 681
- Surface membrane glycoforms, 617
- Surface plasmon resonance, 323
- Swainsonine hydrochloride, 70
- Syndecan-4, 587
- Synthesis
 - of glycosaminoglycans, 795
 - of *N*-pentasaccharides, 361
- T
- T-cells, Mgat5 *N*-glycans regulation of, 26
- T lymphocytes, raft-based signaling in, 191
- Tau-protein, 815
- Teichoic acid, 273
- Temperature dependence, of *Thermus thermophilus* β -glycosidase, 377
- Testis, 787
- Thachypleus tridentatus*, 709
- Thermostability, 377
- Thermozymes, 377
- Thermus caldophilus*, glucosyltransferase of, 36
- Thermus thermophilus*, β -glycosidase of, 377
- Thermus thermosaccharolyticum*, 688
- Tobacco, GnTI coding of, 77
- Topoisomerase II, 301
- Transcription control, of ST6Gal gene, 19
- Transcription factors, glycosphingolipid signaling domain and, 143
- Transformation, in multidrug resistance, 253
- Transforming growth factor- α , inhibition of, 718
- Transglycosylation, of *Thermus thermophilus* β -glycosidase, 377
- Transmembrane signaling, 191
- Trichosanthes japonica*, 671
- Trimannosyl core, 449
- Tritium, 261
- Tritrichomonas mobilensis*, 709
- Trk, 233
- Trypanosoma cruzi*
 - glycoinositolphospholipids from, 727
 - glycosylation mutants in, 71
- Trypanosomal transsialidase, 56
- Trypsin, pancreatic, 787
- Tumor-associated antigens, 531, 627
- Tumor malignancy
 - N*-linked carbohydrate processing inhibitors, 69
 - α 1,3-fucosyltransferase IV on, 69
- Tumor marker, 649
- Tunicamycin, 233
- CFTR and, 808
- fucosyltransferase and, 859
- streptomyces biosynthesis of, 62
- U
- U937 cells, 713
- Ubiquitin, 815
- UDP-galactose 4-epimerase, α 1,3-galactosyltransferase fusion with, 35
- UDP-GlcNAc
 - binding modes of, 38
 - biosynthesis of, 17
 - homology protein model of, 38
- UDP-GlcNAc: α -3-D-mannose β 1,2-*N*-acetylglucosaminyltransferase, 41
 - in *C. elegans* phenotypes, 71
 - in *Drosophila melanogaster*, 72
- UDP-GlcNAc: α -6-D-mannoside β 1,2-*N*-acetylglucosaminyltransferase (GnT II), in *C. elegans* phenotypes, 72
- UDP-glucose, conformational behavior of, 36
- Ulex europaeus* I lectin, 331
- Unnatural glycosidic linkage, 361
- V
- Vaccine
 - antifungal, 677
 - cholera O 139, 425
 - development of, glycosphingolipids in, 638
 - MUC1-based, 653
- Vacuolar systems, lipid membrane domains in, 163
- Verotoxin, in multiple drug resistance, 23
- Vibrio cholerae*
 - attachment platforms of, 173
 - immunogenic conjugate preparation of, 425
 - O139, 425
- Viobriocidal activity, to serotype O139, 425
- Virus cell fusion, 199
- W
- Weak anion exchange chromatography, 401
- Weibel-Palade bodies, α -1,3-fucosyltransferase in, 22
- X
- Xenoantigens, α 1,3-galactosyltransferase and, 15
- Xenotransplantation, α 1,3-galactosyltransferase in, 39
- Xyloglucan biosynthesis, 75
 - fucosyltransferase and galactosyltransferase in, 78
- β 1,2-Xylosyltransferase, *Arabidopsis thaliana* expression of, 77
- Y
- YAC clone transformants, 79
- Yeasts

α 1,2, mannosidase in, 18
dolichols chain length in, 76
mannan conjugation in, 677
protein mannosylation in, 76

Z

Zona pellucida binding, arylsulfatase-A
in, 63